Darovasertib Market Sales

Key Factors Driving Darovasertib Growth

1. First-in-class PKC inhibitor targeting core oncogenic pathway

Darovasertib is a selective protein kinase C (PKC) inhibitor, acting downstream of GNAQ/GNA11 mutations, which are present in ~85–90% of uveal melanoma cases.

Direct targeting of a driver mutation pathway provides strong biological rationale and differentiation vs existing therapies (e.g., immunotherapy).

Positions Darovasertib as a potential disease-modifying targeted therapy, not just symptomatic control.

 

2. Strong clinical efficacy signals in high unmet-need population

In metastatic uveal melanoma (MUM):

57% 1-year overall survival vs ~37% historical benchmark

Median OS ~13.2 months vs ~7 months historically

Combination (darovasertib + crizotinib):

~34% objective response rate (ORR) and 21.1 months median OS in Phase II data

Demonstrates clinically meaningful survival improvement in a disease with very limited options →

Major driver for adoption and regulatory success.

 

3. High unmet need in uveal melanoma (rare but lethal cancer)

Uveal melanoma has:

No widely effective systemic therapies in metastatic setting

Poor prognosis with historical survival ~7–12 months

High unmet need + lack of competition →

Faster uptake post-approval

Potential for premium orphan oncology pricing

Strong physician demand

 

4. Broad development across multiple treatment settings

Darovasertib is being evaluated across:

First-line metastatic uveal melanoma (Phase II/III)

Neoadjuvant and adjuvant settings (Phase II & Phase III)

Multiple combination regimens (e.g., with crizotinib)

Neoadjuvant data shows:

~59% patients with >20% tumor shrinkage

~61% eye preservation rate

Impact:

Multi-line and multi-setting use significantly expands total addressable market (TAM) and treatment duration.

 

5. Regulatory acceleration and late-stage pipeline momentum

Received FDA Fast Track designation for combination therapy in metastatic disease

Breakthrough Therapy Designation (BTD) granted (2025) for neoadjuvant uveal melanoma

Multiple registrational Phase III trials ongoing or planned by 2026

Accelerated regulatory pathways increase probability of:

Faster approval timelines

Earlier commercialization

Competitive first-mover advantage

 

6. Strong combination therapy strategy enhancing efficacy

Combination with crizotinib (MET inhibitor) shows:

Higher response rates vs monotherapy

Durable responses (median duration ~9 months)

Combination regimens could become standard of care, driving:

Higher clinical adoption

Increased treatment duration and revenue per patient

 

Darovasertib Recent Developments

• Servier and IDEAYA Biosciences announced an exclusive license agreement to bring Darovasertib, a promising treatment for a rare eye cancer, to patients worldwide. Under the agreement, Servier obtains the regulatory and commercial rights for darovasertib in all territories outside the United States. IDEAYA retains its rights for darovasertib in the United States. Darovasertib, a potent and selective protein kinase C (PKC) inhibitor, is being developed to broadly address primary and metastatic uveal melanoma (UM). 

“Darovasertib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Darovasertib for potential indication like Uveal melanoma, Colorectal cancer, Malignant melanoma, and Solid tumours in the 7MM. A detailed picture of Darovasertib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Darovasertib for potential indications. The Darovasertib market report provides insights about Darovasertib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Darovasertib performance, future market assessments inclusive of the Darovasertib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Darovasertib sales forecasts, along with factors driving its market.

 

Darovasertib Drug Summary

Darovasertib is an investigational first-in-class oral small-molecule protein kinase C (PKC) inhibitor originally developed by Novartis and licensed to IDEAYA Biosciences, primarily targeting metastatic uveal melanoma (MUM) harboring GNAQ/GNA11 mutations (present in ~90% of cases), with evaluations also in other solid tumors like colorectal cancer and cutaneous melanoma. It selectively inhibits hyperactivated PKC isoforms (e.g., PKCα/β), blocking downstream oncogenic signaling including p-ERK and p-MARCKS pathways activated by mutant GNAQ/11, leading to tumor growth inhibition and promising antitumor activity, particularly in combination with crizotinib (a cMET/ALK inhibitor) via synthetic lethality. Administered at 300 mg twice daily (or weight-based), it has FDA orphan drug designation for uveal melanoma, with phase 2/3 trials (e.g., OptimUM-02, NCT05987332) showing completed enrollment, favorable overall survival data from phase 1/2 (OptimUM-01), and active studies as neoadjuvant/adjuvant therapy, though it remains unapproved as of April 2026. The report provides Darovasertib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the Darovasertib Market Report

The report provides insights into:

• A comprehensive product overview including the Darovasertib MoA, description, dosage and administration, research and development activities in potential indication like Uveal melanoma, Colorectal cancer, Malignant melanoma, and Solid tumours.
• Elaborated details on Darovasertib regulatory milestones and other development activities have been provided in Darovasertib market report.
• The report also highlights Darovasertib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Darovasertib market report also covers the patents information, generic entry and impact on cost cut.
• The Darovasertib market report contains current and forecasted Darovasertib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Darovasertib market report also features the SWOT analysis with analyst views for Darovasertib in potential indications.

 

Methodology

The Darovasertib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Darovasertib Analytical Perspective by DelveInsight

In-depth Darovasertib Market Assessment

This Darovasertib sales market forecast report provides a detailed market assessment of Darovasertib for potential indication like Uveal melanoma, Colorectal cancer, Malignant melanoma, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Darovasertib sales data uptil 2034.

 

Darovasertib Clinical Assessment

The Darovasertib market report provides the clinical trials information of Darovasertib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

 

Darovasertib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

Darovasertib Market Potential & Revenue Forecast

• Projected market size for the Darovasertib and its key indications
• Estimated Darovasertib sales potential (Darovasertib peak sales forecasts)
• Darovasertib Pricing strategies and reimbursement landscape

 

Darovasertib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Darovasertib Market positioning compared to existing treatments
• Darovasertib Strengths & weaknesses relative to competitors

 

Darovasertib Regulatory & Commercial Milestones

• Darovasertib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

Darovasertib Clinical Differentiation

• Darovasertib Efficacy & safety advantages over existing drugs
• Darovasertib Unique selling points

 

Darovasertib Market Report Highlights

• In the coming years, the Darovasertib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Darovasertib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Darovasertib’s dominance.
• Other emerging products for Uveal melanoma, Colorectal cancer, Malignant melanoma, and Solid tumours are expected to give tough market competition to Darovasertib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Darovasertib in potential indications.
• Analyse Darovasertib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Darovasertib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Darovasertib in potential indications.

 

Key Questions Answered In The Darovasertib Market Report

• What is the class of therapy, route of administration and mechanism of action of Darovasertib? How strong is Darovasertib’s clinical and commercial performance?
• What is Darovasertib’s clinical trial status in each individual indications such as Uveal melanoma, Colorectal cancer, Malignant melanoma, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Darovasertib Manufacturers?
• What are the key designations that have been granted to Darovasertib for potential indications? How are they going to impact Darovasertib’s penetration in various geographies?
• What is the current and forecasted Darovasertib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Darovasertib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to Darovasertib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Darovasertib? What is the duration of therapy and what are the geographical variations in cost per patient?